Theoret James R, Li Jihong, Navarro Mauricio A, Garcia Jorge P, Uzal Francisco A, McClane Bruce A
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
California Animal Health and Food Safety Laboratory, San Bernardino Branch, School of Veterinary Medicine, University of California-Davis, San Bernardino, California, USA.
Infect Immun. 2017 Dec 19;86(1). doi: 10.1128/IAI.00730-17. Print 2018 Jan.
Many strains produce NanI as their major sialidase. Previous studies showed that NanI could potentiate epsilon toxin cytotoxicity by enhancing the binding of this toxin to host cells. The present study first determined that NanI exerts similar cytotoxicity-enhancing effects on enterotoxin and beta toxin, which are also important toxins for diseases (enteritis and enterotoxemia) originating in the gastrointestinal (GI) tract. Building upon previous work demonstrating that purified trypsin can activate NanI activity, this study next determined that purified chymotrypsin or mouse intestinal fluids can also activate NanI activity. Amino acid sequencing then showed that this effect involves the N-terminal processing of the NanI protein. Recombinant NanI (rNanI) species corresponding to major chymotrypsin- or small intestinal fluid-generated NanI fragments possessed more sialidase activity than did full-length rNanI, further supporting the proteolytic activation of NanI activity. rNanI species corresponding to proteolysis products also promoted the cytotoxic activity and binding of enterotoxin and beta toxin more strongly than did full-length rNanI. Since enterotoxin and beta toxin are produced in the intestines during human and animal disease, these findings suggest that intestinal proteases may enhance NanI activity, which in turn could further potentiate the activity of intestinally active toxins during disease. Coupling these new results with previous findings demonstrating that NanI is important for the adherence of to enterocyte-like cells, NanI sialidase is now emerging as a potential auxiliary virulence factor for enteritis and enterotoxemia.
许多菌株将NanI作为其主要的唾液酸酶。先前的研究表明,NanI可通过增强这种毒素与宿主细胞的结合来增强ε毒素的细胞毒性。本研究首次确定,NanI对肠毒素和β毒素也具有类似的细胞毒性增强作用,而这两种毒素对于源自胃肠道(GI)的疾病(肠炎和肠毒血症)也是重要毒素。基于先前证明纯化的胰蛋白酶可激活NanI活性的工作,本研究接下来确定纯化的胰凝乳蛋白酶或小鼠肠液也可激活NanI活性。氨基酸测序随后表明,这种作用涉及NanI蛋白的N端加工。与主要由胰凝乳蛋白酶或小肠液产生的NanI片段相对应的重组NanI(rNanI)物种比全长rNanI具有更高的唾液酸酶活性,进一步支持了NanI活性的蛋白水解激活。与蛋白水解产物相对应的rNanI物种也比全长rNanI更强烈地促进肠毒素和β毒素的细胞毒性活性及结合。由于在人类和动物疾病期间肠毒素和β毒素在肠道中产生,这些发现表明肠道蛋白酶可能增强NanI活性,这反过来可能在疾病期间进一步增强肠道活性毒素的活性。将这些新结果与先前表明NanI对[细菌名称]黏附于肠上皮样细胞很重要的发现相结合,NanI唾液酸酶现在正成为肠炎和肠毒血症的一种潜在辅助毒力因子。 (注:原文中部分[细菌名称]未明确写出,翻译时保留原样)